The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Kite, a Gilead company
Differential expression of melanoma-associated antigen A3/6 and associated immune molecules prior to and post treatment with immune checkpoint inhibitors (ICI) in patients with mUC.
 
Izak Faiena
No Relationships to Disclose
 
Samuel Aaron Funt
Stock and Other Ownership Interests - Allogene Therapeutics; Hubble (I); Kite, a Gilead company; Kronos Bio (I); Neogene Therapeutics (I); Second Science; Urogen pharma (I); Vida Ventures (I)
Consulting or Advisory Role - AstraZeneca/MedImmune (Inst)
Research Funding - AstraZeneca (Inst); Decibel Therapeutics (Inst); Genentech/Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb
 
Stephanie H. Astrow
Employment - Kite, a Gilead company
Stock and Other Ownership Interests - Kite, a Gilead company
 
Tanya B. Dorff
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen Oncology; Noxopharm; Roche; Seagen
Speakers' Bureau - Exelixis; Prometheus
Research Funding - Bayer; Bristol-Myers Squibb
 
Sabina Adhikary
Employment - Kite, a Gilead company
Stock and Other Ownership Interests - Kite/Gilead
 
Tristan Gorgan
No Relationships to Disclose
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Clinical Care Options; ClinicalMind; Intellisphere; Medscape; Peerview; Research To Practice; UpToDate; Vindico
Consulting or Advisory Role - Adicet Bio; Agensys; Astellas Pharma; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Fortress Biotech; GlaxoSmithKline; Inovio Pharmaceuticals; Janssen Oncology; Lilly; Merck; Pharmacyclics; QED Therapeutics; Roche/Genentech; Seagen; Sensei Biotherapeutics; western oncolytics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Seagen (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche
 
David Elashoff
No Relationships to Disclose
 
Allan J. Pantuck
Leadership - Kyn therapeutics
Stock and Other Ownership Interests - Alimera Sciences; Endocyte; Evolus; Kyn therapeutics; Urogen pharma
Consulting or Advisory Role - Pfizer
Expert Testimony - Breckenridge Pharmaceuticals
Travel, Accommodations, Expenses - Pfizer
 
Alexandra Drakaki
Employment - Kyn therapeutics (I)
Leadership - Kyn therapeutics (I)
Stock and Other Ownership Interests - Alimera Sciences (I); Athos Therapeutics (I); Kyn therapeutics (I); Urogen pharma (I)
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Kyn therapeutics; RADMETRIX; Seagen
Research Funding - Kite/Gilead
Patents, Royalties, Other Intellectual Property - My significant other has 5 patents with UCLA. (I)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Seagen